Cargando…

Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells

BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xuxiu, Geng, Jiajia, Zhang, Jinman, Miao, Jinlai, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769755/
https://www.ncbi.nlm.nih.gov/pubmed/31527518
http://dx.doi.org/10.3390/antiox8090402
_version_ 1783455311880781824
author Lu, Xuxiu
Geng, Jiajia
Zhang, Jinman
Miao, Jinlai
Liu, Ming
author_facet Lu, Xuxiu
Geng, Jiajia
Zhang, Jinman
Miao, Jinlai
Liu, Ming
author_sort Lu, Xuxiu
collection PubMed
description BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strategy for CML therapy is to degrade BCR-ABL using small molecules. Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. In this study, we showed XN could inhibit the proliferation, induce S phase cell cycle arrest, and stimulate apoptosis in K562 cells. XN degraded BCR-ABL in a concentration- and time-dependent manner, and the involved degradation pathway was caspase activation, while not autophagy induction or ubiquitin proteasome system (UPS) activation. Moreover, we revealed for the first time that XN could inhibit the UPS and autophagy in K562 cells, and the inhibitory effect of XN on autophagy could attenuate imatinib-induced autophagy and enhance the therapeutic efficiency of imatinib in K562 cells. Our present findings identified XN act as a degrader of BCR-ABL in K562 cells, and XN had potential to be developed as an alternate agent for CML therapy.
format Online
Article
Text
id pubmed-6769755
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67697552019-10-30 Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells Lu, Xuxiu Geng, Jiajia Zhang, Jinman Miao, Jinlai Liu, Ming Antioxidants (Basel) Article BCR-ABL oncoprotein drives the initiation, promotion, and progression of chronic myelogenous leukemia (CML). Tyrosine kinase inhibitors are the first choice for CML therapy, however, BCR-ABL mediated drug resistance limits its clinical application and prognosis. A novel promising therapeutic strategy for CML therapy is to degrade BCR-ABL using small molecules. Antioxidant xanthohumol (XN) is a hop-derived prenylated flavonoid with multiple bioactivities. In this study, we showed XN could inhibit the proliferation, induce S phase cell cycle arrest, and stimulate apoptosis in K562 cells. XN degraded BCR-ABL in a concentration- and time-dependent manner, and the involved degradation pathway was caspase activation, while not autophagy induction or ubiquitin proteasome system (UPS) activation. Moreover, we revealed for the first time that XN could inhibit the UPS and autophagy in K562 cells, and the inhibitory effect of XN on autophagy could attenuate imatinib-induced autophagy and enhance the therapeutic efficiency of imatinib in K562 cells. Our present findings identified XN act as a degrader of BCR-ABL in K562 cells, and XN had potential to be developed as an alternate agent for CML therapy. MDPI 2019-09-16 /pmc/articles/PMC6769755/ /pubmed/31527518 http://dx.doi.org/10.3390/antiox8090402 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lu, Xuxiu
Geng, Jiajia
Zhang, Jinman
Miao, Jinlai
Liu, Ming
Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title_full Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title_fullStr Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title_full_unstemmed Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title_short Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
title_sort xanthohumol, a prenylated flavonoid from hops, induces caspase-dependent degradation of oncoprotein bcr-abl in k562 cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769755/
https://www.ncbi.nlm.nih.gov/pubmed/31527518
http://dx.doi.org/10.3390/antiox8090402
work_keys_str_mv AT luxuxiu xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells
AT gengjiajia xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells
AT zhangjinman xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells
AT miaojinlai xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells
AT liuming xanthohumolaprenylatedflavonoidfromhopsinducescaspasedependentdegradationofoncoproteinbcrablink562cells